1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

  • March 2014
  • -
  • GlobalData
  • -
  • 69 pages

Summary

Table of Contents

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

Summary

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Merck is developing V503, a nine-valent HPV vaccine; like Gardasil, this vaccine is being developed in partnership with CSL, from which Merck is licensing VLP technology. Both V503 and Merck’s current vaccine Gardasil have a similar mechanism of action, consisting of VLPs combined with aluminum salt adjuvant, delivered as an IM injection over a three-dose course. Merck has recently registered a Phase III trial to assess the immunogenicity of V503 given over a two-dose course (Merck, NCT01984697).

Scope

- Overview of HPV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on V503 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for V503 for the top eight countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Canada and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HPV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of V503 performance
- Obtain sales forecast for V503 from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Canada and Australia)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
2017-2021 World Sexually-Transmitted Disease (STD) Diagnostics Market: Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis--Supplier Shares, Sales Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation

2017-2021 World Sexually-Transmitted Disease (STD) Diagnostics Market: Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis--Supplier Shares, Sales Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation

  • $ 9600
  • Industry report
  • January 2017
  • by Venture Planning Group

About this Report This report presents a detailed analysis of the STD market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.  Current scientific views on epidemiology and etiology are ...

2017 Competing in the Global Sexually-Transmitted Disease (STD)Testing Market

2017 Competing in the Global Sexually-Transmitted Disease (STD)Testing Market

  • $ 9600
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200. This new 350-page report from VPGMarketResearch.com contains 90 tables and provides analysis of the global s ...

2017-2021 Sexually-Transmitted Diseases (STD) Diagnostic Testing Market

2017-2021 Sexually-Transmitted Diseases (STD) Diagnostic Testing Market

  • $ 6200
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200. This new 350-page report from VPGMarketResearch.com contains 90 tables and provides analysis of the global s ...


Download Unlimited Documents from Trusted Public Sources

Influenza Statistics in Germany

  • April 2017
    11 pages
  • Influenza  

  • Germany  

    Europe  

View report >

Infectious Disease Statistics in the US

  • April 2017
    7 pages
  • Tuberculosis  

    Sexually Transm...  

    Infectious Dise...  

  • United States  

    World  

View report >

Sexually Transmitted Disease Statistics in the US and North America

  • April 2017
    130 pages
  • Sexually Transm...  

    Health Care Pro...  

  • North America  

    United States  

View report >

Hiv Aids Statistics

26 days ago

Related Market Segments :

Sexually Transmitted Disease

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.